Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
about
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenNSABP breast cancer clinical trials: recent results and future directionsCholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancerLetrozole sensitizes breast cancer cells to ionizing radiationAdvances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapyClinical utility of letrozole in the treatment of breast cancer: a Chinese perspectiveCurrent Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast CancerOptimal management of hormone receptor positive metastatic breast cancer in 2016Application of metabolomics in drug resistant breast cancer researchManagement of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment optionsReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantRole of positron emission tomography for the monitoring of response to therapy in breast cancerClinical utilities of aromatase inhibitors in breast cancerEndocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersInhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistanceAromatase inhibitors and inactivators in breast cancerEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerThe Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?Heel ultrasound can assess maintenance of bone mass in women with breast cancer.Role of nuclear receptor SHP in metabolism and cancer.Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivoClinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.Breast cancer (metastatic).In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.Aromatase inhibitors-induced bone loss in early breast cancer.Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma.Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancerInvestigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinoline and uracil derivatives.Adjuvant Endocrine Therapy in Early Postmenopausal Breast CancerAn overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.Tracking progesterone receptor-mediated actions in breast cancerChemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases.The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuumAnti-aromatase agents in the treatment and prevention of breast cancer.The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsDrug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.
P2860
Q24239985-AE2028BE-3637-4ABB-8104-00B13A669A6FQ24246391-F3709468-449A-4A23-BE54-AD22F434F505Q24520573-EDA1E67E-061D-4AF1-8BDC-7B7DC7D2D54CQ24658633-91B82420-587B-4148-AF4D-A4B151103BFBQ24797004-36368FCC-4FEB-4E3D-BB4F-68BC8A61003AQ24803990-8E3B030C-7AD6-4DAA-A79E-CB4D8054B803Q26752834-93596F4C-D097-4C20-8AE1-8F13EFEC4FD9Q26764987-74CEDB6F-0D23-4ECE-BD4D-4E8FB4EE6E35Q26777683-FA107CFC-2452-4CF8-925F-3929FB5938FDQ26866291-951558A0-BC39-4833-BFC2-643C57DF30E3Q26995549-04D99441-1398-46F5-9BCE-C5481EE1D832Q28076777-A7821FA6-E70A-477A-81DA-AEBDF36F5B05Q28080621-BF8E2AAA-F722-4AA8-BBCA-0D8C9862480BQ28081168-4CD04353-0C15-470F-A68F-88C49B0B0F9CQ28081872-1BCB9089-7F9B-480F-9E7F-B3EE56D4060CQ28237217-391563DD-DEA8-497F-B94B-138C5EB311F4Q28362331-3516D4E2-21E4-40E8-8E50-057969DDEE80Q29620676-C24836E4-C898-4621-BCFA-8163C8D74204Q30234511-1F90559D-9AE5-4F0D-B720-DC73ED70A59FQ30383587-6BCADDE0-DF08-4E5F-AA2A-A0B73B04C8F8Q30395192-D1B75CA6-4A0E-416E-8C0B-18D308C354C9Q30438048-02719BB5-6E1D-4AE4-9142-DD48F3C83429Q33197385-6B1682D7-7CA8-4503-9030-31A3362A4551Q33321322-4BC91D0D-1DD6-4FC6-A83E-4F072B85DA34Q33448016-1A09609F-0626-4903-8F22-A9DDAC977100Q33468636-44C12EF1-143B-45F2-960D-CB20848608E5Q33531646-D853308F-2C7E-4012-913F-608B90924D04Q33584169-FA57B75A-8AF8-4C25-8B6E-E5F17A183F4BQ33752867-6A713002-FA2F-443A-90BF-3FC9EE5E4D44Q33943265-58FC8534-B26D-4772-855A-0056EC475EF6Q33944557-748637C2-7AFC-45DA-8C99-0A2A19B4E6E4Q34074415-E03EBAEE-CF73-4917-9C9A-C007DBFE729CQ34096283-AE2819BC-3DB7-4ADE-AAFE-BDAE72CC0B4BQ34156603-4CC11903-02FF-4B20-B3F6-B68593806E48Q34388848-807FA3ED-44AF-42C3-AFA8-D87A07BB8FB6Q34563336-A38252A2-BBD2-446D-BC44-3C937E98AFA4Q34592879-A5C9D002-8DE4-4249-94E1-34BDD57C8844Q34608612-4279D442-2488-44CA-9AC0-DBE7644C205CQ34617864-240F943E-88D0-4CD3-AB3E-542BAAF6B651Q34658267-4DFE9E65-0238-49AA-8F36-3EA78D997264
P2860
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Superior efficacy of letrozole ...... Letrozole Breast Cancer Group.
@en
Superior efficacy of letrozole ...... Letrozole Breast Cancer Group.
@nl
type
label
Superior efficacy of letrozole ...... Letrozole Breast Cancer Group.
@en
Superior efficacy of letrozole ...... Letrozole Breast Cancer Group.
@nl
prefLabel
Superior efficacy of letrozole ...... Letrozole Breast Cancer Group.
@en
Superior efficacy of letrozole ...... Letrozole Breast Cancer Group.
@nl
P2093
P1476
Superior efficacy of letrozole ...... Letrozole Breast Cancer Group.
@en
P2093
A Pluzanska
B Staffler
D Becquart
E Salminen
H A Chaudri-Ross
H Mouridsen
H P Sleeboom
P304
P356
10.1200/JCO.2001.19.10.2596
P407
P577
2001-05-01T00:00:00Z